Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Cancers|June 2, 2021
Precision Therapy for Mesothelioma: Feasibility and New OpportunitiesSean Dulloo, Aleksandra Bzura, Dean Anthony Fennell
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 11, 2023
Family Matters: Germline Testing in Thoracic CancersFeighanne Hathaway, Renato Martins, Steven Sorscher, et al.
Drugs|July 13, 2024
Targeting DNA Damage Response Deficiency in Thoracic CancersAleksandra Bzura, Jake B Spicer, Sean Dulloo, et al.
Oncogene|December 22, 2022
BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanismsAnita Singh, Sara Busacca, Aarti Gaba, et al.
Blood Advances|August 8, 2018
CD40L/IL-4-stimulated CLL demonstrates variation in translational regulation of DNA damage response genes including ATMLarissa Lezina, Ruth V Spriggs, Daniel Beck, et al.
BMJ Open|November 22, 2023
Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centresDean Fennell, Daniel Griffiths, Zina Eminton, et al.
Cancer Research|November 10, 2022
ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy ResistanceMassimiliano Mellone, Klaudia Piotrowska, Giulia Venturi, et al.
Nature Communications|July 14, 2026
Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancerVictoria Gibson, Joanna Dzialo, Terri Messier, et al.
Nature Communications|March 20, 2021
Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironmentMin Zhang, Jin-Li Luo, Qianqian Sun, et al.
Nature Communications|July 21, 2025
Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trialDean A Fennell, Kayleigh Hill, Min Zhang, et al.
Pageof 2